AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05861050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT05861050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT05861050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT03973710 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei dietary supplement
Description: a commercial probiotic dietary supplement
Study NCT04899687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Dextromethorphan, an over-the-counter cough suppressant, will be taken by mouth twice daily for four weeks of the study, starting at 15mg per dose, and increasing weekly as tolerated to a maximum of 60mg per dose.
Study NCT03973710 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo controls
Description: placebo with a similar appearance to probiotics supplement
Study NCT05452473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDSS-assisted upper GI endoscopy
Description: Expert endoscopists perform screening upper gastrointestinal endoscopy while looking at the monitor (CDSS system: automatic detection or lesion classification function) and listening to the sound of the monitor next to the original endoscopy monitor system.
Study NCT05452473 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no intervention
Description: Expert endoscopists perform routine screening upper gastrointestinal endoscopy without CDSS's help.
Study NCT06545006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isometric contractions
Description: Participants will perform 20 minutes of isometric contractions in different positions, with contraction durations of 10 seconds and a number of repetitions between 4 and 10, depending on their progress in the training program.
Study NCT06271213 — intervention group
Intervention type: OTHER
Intervention: observational only - no interventions as part of study
Description: Children with asthma will be receiving biologics therapy as part of their standard of care - unrelated to this study design. All cohorts will be observed without study intervention.
Study NCT04443010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onfekafusp alfa
Description: This is an open label phase 1/2/2b study in subjects with newly diagnosed glioblastoma.~The study will be conducted in three consecutive parts: First the dose finding part to determine the RD of L19TNF in combination with chemoradiotherapy, followed by a signal seeking part that investigates first signs of activity and then an activity evaluation part that studies the efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone.
Study NCT04443010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Patients will receive radiotherapy and TMZ. Treatment start with chemoradiotherapy is foreseen after surgical resection or biopsy of glioblastoma
Study NCT04443010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients will receive radiotherapy and TMZ. Treatment start with chemoradiotherapy is foreseen after surgical resection or biopsy of glioblastoma
Study NCT04651244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Gold standard for identifying inflammatory changes in patients with acute pyelonephritis
Study NCT04651244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound performed by a radiologist
Description: US performed by a radiologist including standard grayscale evaluation of the kidneys, Doppler US and contrast enhanced US (CEUS).
Study NCT04651244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care ultrasound
Description: Point of care US by a study assistant with basic ultrasound skills and training to access the presence or absence of hydronephrosis. If hydronephrosis is present it will be graded into one of four categories.
Study NCT06476925 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sonar guided stellate ganglion injection
Description: using high frequency probe, sonar guided stellate ganglion block with 8 ml saline 0.9%
Study NCT06476925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sonar guided stellate ganglion block
Description: using high frequency probe, sonar guided stellate ganglion block with 8 ml bupivacaine 0.25%
Study NCT05230680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACHOP
Description: 1. Phase I Azacitidine D-2\~D1, starting from dose level 1. Based on the BOIN design described above, if no DLT is identified in level 1, the dose will be escalated stepwise to levels 2, 3, and then 4.~   Azacitidine combined with CHOP regimen every 3 weeks as below:~  * Level 1 - Azacitidine 50mg/m2 D-2, -1, 1~  * Level 2 - Azacitidine 75mg/m2 D-2, -1, 1~  * Level 3 - Azacitidine 100mg/m2 D-2, -1, 1~  * Level 4 - Azacitidine 125mg/m2 D-2, -1, 1~   Azacitidine at each level will be combined with the corresponding CHOP regimen as follows:~  * Cyclophosphamide 750mg/m2 d1~  * Doxorubicin 50 mg/m2 d1~  * Vincristine 1.4 mg/m2 (Max: 2 mg) d1~  * Prednisolone 100mg PO d1-5~2. Phase II~   * Azacitidine determined dose daily for D-2, -1, 1~  * CHOP (Cyclophosphamide 750mg/m2 d1, Doxorubicin 50 mg/m2 d1, Vincristine 1.4 mg/m2 (Max: 2 mg) d1, Prednisolone 100mg PO d1-5), 6 cycles in total
Study NCT06077461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mandala painting
Description: Patients in this group will be subjected to mandala painting.
Study NCT05675358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Oculus Quest 2 256 GB All-In-One Vr Virtual Reality Glasses were used in the study.
Study NCT05230875 — intervention group
Intervention type: BEHAVIORAL
Intervention: self-administered questionnaire
Description: All patients participating in the therapeutic education program will complete a self-administered questionnaire before participation in educational program.~A new identical self-questionnaire will be distributed to patients 3 to 6 months after their participation in the therapeutic education program.
Study NCT05302713 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ionic Calcium
Description: Ionic calcium (IC), a calcium in a free ionic state (i.e., non-protein bound), is purported to improve calcium uptake and homeostasis leading to improved cellular signaling that may have been disrupted through environmental and lifestyle stressors.
Study NCT05302713 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: Calcium carbonate supplementation in a solution identical in appearance, consistency, and taste to the intervention supplement.
Study NCT04258410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral soft chew
Description: placebo identical to experimental drug contained in soft chew
Study NCT04258410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin
Description: experimental drug contained in soft chew
Study NCT04889664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Repeated intravenous Ketamine infusions.
Study NCT04889664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Description: WET is a brief, 5-session evidence-based written trauma-focused therapy
Study NCT06394791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab + IL-2 Combined with Capox
Description: Tislelizumab + IL-2 Combined with Capox
Study NCT06424977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomarker Targeted Stimulation (BTS)
Description: Using continuous stimulation to target multiple network nodes, Biomarker Targeted Stimulation (BTS) is intended to suppress abnormal interictal activity, as determined by biomarkers including interictal epileptiform discharges (IED) and high frequency oscillations (HFO), with the intention to reduce brain hyperexcitability, thereby limiting seizure occurrence.
Study NCT04960176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture will be applied by using 0,25x25mm needles.
Study NCT04960176 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Non-invasive Sham Acupuncture
Description: Non-invasive sham acupuncture will be applied by using blunted 0,25x25mm needles.
Study NCT05623384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: A cross-sectional scan with a high-frequency line array probe reveals the pre-C6 transverse nodule or C7 transverse process, and the structures of the thyroid, carotid sheath, vertebral artery, inferior thyroid artery, trachea, and esophagus are identified by observation. The carotid sheath is pushed out as far as possible laterally, the needle is inserted in the paratracheal sulcus, and the tip of the needle is passed through the lateral border of the thyroid into the deep anterior fascial surface of the long cervical muscle.After backdrawing no blood, cerebrospinal fluid or gas, 5 ml of lidocaine was injected.（lidocaine 80mg；Physiological saline 1ml）
Study NCT05623384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facial and glossopharyngeal nerve blocks
Description: The operator touches the position of the mastoid process and needles vertically at the front of the mastoid process directly below the external auditory canal. When the surface of the mastoid is touched, the needle is adjusted to pass through the front of the mastoid and then slowly needled for about 1 cm, and when the patient develops swelling and pain, 3 ml of the drug is injected. then the needle is slowly needled backward for about 1 cm, and when the patient develops swelling and pain, 2 ml of the drug is injected. （mecobalamin injection 1mg；lidocaine 20mg； dexamethasone 10mg ；Physiological saline 2ml）
Study NCT05623384 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mecobalamin Tablets
Description: oral Mecobalamin Tablets tid-8
Study NCT05623384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin Tablets
Description: oral Mecobalamin Tablets tid-8
Study NCT06545006 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: isometric contractions
Description: Participants will perform 20 minutes of isometric contractions in different positions, with contraction durations of 10 seconds and a number of repetitions between 4 and 10, depending on their progress in the training program.
Study NCT06545006 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: stroboscopic glasses
Description: This training involves performing skill exercises with a rugby ball while wearing stroboscopic glasses. The glasses have alternating opaque and clear sections, causing multiple and/or fragmented vision.~The goal is to improve the processing of visual information at the level of higher functions. This aids in decision-making. It does not involve the same structures and functions implicated in reflexive muscle recruitment strategies as the Quick Release, so it should not be a confounding factor. However, it provides a beneficial, stimulating, and enjoyable training session, increasing subject adherence as they work on a skill useful in their sport.
Study NCT06405555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Oral Tablet
Description: Exposure to up to 5 days of midodrine (or until hospital discharge) in hospital at escalating doses with the following protocol: 2.5 mg po TID x 1 day, 5.0 mg po TID x 1 day, 7.5 mg po TID x 1 day, 10 mg po TID x 2 days.
Study NCT06545006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quick Release
Description: The distance (in mm) of the anterior head translation will be measured using a linear displacement sensor. The subject will be instructed to recruit their extensor muscles as quickly and as strongly as possible to minimise the head displacement distance. They will be aware of their score after each repetition (real-time feedback).~Subjects must react to a rapid forward displacement of the cervical spine, without impact. To generate this forward displacement without impact, subjects are positioned with support in front of the forehead, holding their head and neck. The subject must exert an isometric flexion effort against this frontal support (energy storage), with the intensity set by the examiner based on the Maximum Isometric Force measured during a prior maximal isometric test. The frontal resistance will suddenly release, and the head displacement in the sagittal plane will be measured until the recruitment of the cervical spine extensor muscles stops this displacement
Study NCT05967247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The experimental group used App for MBSR intervention
Description: The experimental group used App for MBSR intervention The main app of this experiment is Mindfulness in Life (Taiwan) (this system is only applicable to Android devices). The content is divided into two parts. The course is compressed and simplified, mainly focusing on mindfulness learning and practicing audio-visuals. There are eight-week themed audio-visuals and mindful caring words guided by mindfulness-based stress reduction, mindfulness-stretching guidance, and the function of recording the reading time of the research subjects. App platform for researchers to communicate.
Study NCT05967247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the Heart Care Life app
Description: Control group serves as a waiting list with priority given to placebo Placebo for the Heart Care Life app.
Study NCT06286059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine
Description: In addition to the conventional management, patients will receive phentolamine (Rogitamine; Egypharma) infusion at a rate of 0.5 μgm/kg/min for the first 15 minutes after a bolus dose of 5 mg. If significant hemodynamic change occurred, the infusion then will be discontinued and the patient will be excluded. Otherwise, the dose will be uptitrated gradually 0.5-2 ugm/kg/min and the infusion will be continue for 12 hours.
Study NCT05528302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tech-CBT intervention
Description: The Tech-CBT intervention is a manualised package that incorporates Cognitive Behavioural Therapy methods.
Study NCT05967247 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: the Heart Care Life app
Description: Control group serves as a waiting list with priority given to placebo Placebo for the Heart Care Life app.
Study NCT05967247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APP
Description: APP
Study NCT05967247 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: APP
Description: APP
Study NCT04856878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: The investigational drug vancomycin is administered intravenously through a newly inserted peripheral or central venous catheter directly after removal of the 'old' catheters. The investigational drug is administered with a volume of 500ml normal saline (NaCl 0.9%) with a rate of maximal 1g per hour.
Study NCT05333458 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT05333458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05333458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05333458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05165849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFS101A
Description: GFS101A will be administrated intravenously Q3W.
Study NCT05165849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab with fixed dose of 240 mg Q3W administered intravenously.
Study NCT04694248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: For anticoagulant, it is rivaroxaban 20mg once a day for 6 months.
Study NCT04694248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
Study NCT04644185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCTA01
Description: SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody
Study NCT04644185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: all SCTA01 excipients without active component+best supportive care
Study NCT06163586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neonatal Touch and Massage Therapy
Description: Structured touch and massage therapy performed by certified providers.
Study NCT04572217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate (starting dose 25 mg daily, max dose 100 mg daily)
Study NCT04572217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Phentermine (starting dose 8 mg, max dose 16 mg)
Study NCT06460948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone Acetate-Ethinyl Estradiol
Description: Estrogen-progestin will be given to participants in both cohorts, arginine-vasopressin deficiency cohort and healthy control cohort.
Study NCT05814432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single high dose of liposomal amphotericin B
Description: Single high dose (10 mg/kg) of liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS
Study NCT05814432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-AmB standard dose
Description: Standard treatment (3 mg/kg for two weeks) with liposomal amphotericin B as induction therapy for disseminated histoplasmosis in AIDS
Study NCT06130787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood and bone marrow sample
Description: Individual biological aging determined by DNA methylation analysis will be assessed at D0, M3 and M12.~An optional bone marrow sample will be taken during the myelogram performed at diagnosis.~Individual fragility and quality of life will be assessed using geriatric tools at D0, M6, M12, M24 and M36
Study NCT05333458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06043622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography angiography
Description: Optical coherence tomography angiography
Study NCT06043622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ophthalmological exam
Description: ophthalmological exam
Study NCT04732845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fully human anti CD19 CAR-T Cell Dose
Description: Level -1 (1 x 10\^5 cells/kg) Level 1 \[Starting Dose\] (5 x 10\^5 cells/kg) Level 2 (1 x 10\^6 cells/kg) Level 3 (2 x 10\^6 cells/kg)~Infusion of CAR-T cells will occur over 5-30 minutes.
Study NCT04732845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 daily from day -5 to -3
Study NCT04732845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60mg/Kg on day -6
Study NCT06308133 — intervention group
Intervention type: OTHER
Intervention: apheresis procedure
Description: collection of hematopoietic stem cells carried out using the single-chamber and continuous mononuclear cell (cMNC) collection system with Spectra Optia (Terumo BCT)
Study NCT06441903 — intervention group
Intervention type: OTHER
Intervention: Ultrasound
Description: Through systematic ultrasound visualization of the pectoralis major muscle, we seek to directly visualize and characterize the different intra- and extra-muscular connective structures of the muscle - Delto Pectoral Tendon (DPT) , Distal Pectoralis Major Tendon (PMT), Anterior Deltoid Tendon (ADT), Anterior Pretendinous Lamina of the Pectoralis Major (ALPM), Posterior Pretendinous Lamina of the Pectoralis Major (PLPM) and Deep Fascia of the Pectoral Major (DFPM) - constituting its connective skeleton, with particular attention to its distal portion near the humerus and on the search for this DPT tendon.
Study NCT05118360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC41 2 mg
Description: 2mg of ASC41 orally once daily for 52 weeks
Study NCT05118360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC41 4 mg
Description: 4mg of ASC41 orally once daily for 52 weeks
Study NCT05118360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo orally once daily for 52 weeks.
Study NCT06121258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video series
Description: The intervention is a web-based educational video series that was developed using a patient-centered approach that discusses breast cancer treatment, sexual health side effects, and provides treatment and mitigation strategies for these side effects.
Study NCT05049811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mini program
Description: To design, construct, and test the mini program in patients managing cancer pain
Study NCT05049811 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: conventional pharmaceutical care
Description: Regular education includes medication guidance from doctors, nurses and pharmacists.
Study NCT05796440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM-201
Description: Administered orally once daily
Study NCT04628026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy